3.02
+2.03%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Psyence Biomedical
Its shares trade under the ticker PBM. It has been listed since 10 December 2021.
Psyence Biomedical Ltd is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 10 Dec 2021
- Website
- psyence.com ↗
- Head office
- 121 RICHMOND STREET WEST PENTHOUSE, TORONTO
- Incorporated in
- A6
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Michael JordaanChairman of the Board, since 2021
- Mr. Marc BalkinChief Executive Officer, Director, since 2021
- Mr. Jurgen Van De VyverChief Financial Officer
- Mrs. Simran AggarwalIndependent Director
- Mr. Rohit BodasIndependent Director
- Mrs. Nicole FarbIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Psyence Biomedical Ltd develops natural psilocybin products for psychological trauma healing in palliative care.
- The company partners with iNGENu, an Australia-based CRO with psychedelic drug development expertise.
- PEX010, a 25mg naturally derived psilocybin drug candidate, is in Phase IIb clinical trial.
Weaknesses
- The company operates in a highly regulated industry with limited market access in most countries.
- Psyence Biomedical Ltd has no products approved for market use yet.
- The clinical trial phase may face delays or regulatory hurdles in palliative care settings.
Opportunities
- The growing demand for natural mental health treatments in palliative care presents a market opportunity.
- Collaboration with iNGENu in Australia expands global clinical research capabilities.
- Psilocybin-based therapies could gain regulatory approval in more countries over time.
Threats
- Regulatory restrictions on psilocybin use in many countries limit market expansion.
- Competition from other psychedelic drug developers may emerge in the future.
- Public perception challenges regarding psychedelic substances could affect adoption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.